Is Metabolic Associated Fatty Liver Disease Common in Chronic Kidney Disease Patients?

Abstract

Introduction: Metabolic associated fatty liver disease (MAFLD) chosen as a term to encompass fatty liver disease and metabolic issues in patients, this illness was called non-alcoholic fatty liver disease. About 10% to 15% of the world's population lives with chronic kidney disease (CKD). Damage to the kidneys, either structurally or functionally, that lasts longer than three months characterizes this progressive disease. The mechanisms that cause both the buildup of fat in the liver and the impairment of the kidneys are interrelated. However, further research is needed to definitively link MAFLD to chronic kidney disease (CKD). Aim of the study: Our objective was to assess the frequency of MAFLD in CKD patients and examine the variables that contribute to the development of MAFLD in these individuals. Materials& Methods: The study we did is an observational cross-sectional study that took place from January to December 2023. The study encompassed a cohort of 108 individuals diagnosed with chronic kidney disease (CKD), all of them were at least 18 years of age and underwent therapy at the outpatient clinic of Renal and Urology Minia university hospital. The patients had a comprehensive assessment, including clinical examination, anthropometric measurements, biochemical analysis, and ultrasound imaging.